| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Major depressive disorder (MDD) and associated mood syndromes, which are estimated to affect more than 21 million individuals in the United States,1 are among the most common mental health disorders and a continually expanding burden on healthcare systems. For patients affected by these complex syndromes, which vary in clinical presentation, timely, effective treatment can have a positive impact on their quality of life. Key to successful outcomes is determining the right psychotropic medication.
Targeted testing for optimized outcomes
Understanding if a patient is affected by genetic variation associated with altered metabolism of certain medications that make them resistant to treatment is integral to guiding treatment selection. Pharmacogenomics (PGx), or genetic testing used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.
Incorporating PGx testing into clinical practice as an adjunct to or in advance of therapeutic drug monitoring (TDM), which quantifies drug concentrations in the blood, provides physicians and psychiatrists with personalized insights to identify and avoid adverse drug reactions. In instances of poor treatment response, PGx facilitates developing individualized treatment plans based on probable medication response. This approach not only maximizes therapeutic efficacy, it minimizes toxicity, improves medication adherence, and lowers overall costs.5 For optimal outcomes, both PGx and TDM must be interpreted in the full context of a patient’s clinical picture, including demographic and clinical characteristics.
Results from our comprehensive panel can increase understanding of an individual’s genetic makeup to help personalize dosing decisions.
Key testing
Highlights
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for patients across a variety of specialities.
Inter-individual differences in tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) pharmacokinetic parameters and treatment outcomes are associated with CYP2D6 and CYP2C19 genetic variants. With some drugs being affected by CYP2D6 only (e.g., amitriptyline) and others by both polymorphic enzymes (e.g., clomipramine), focused testing is recommended.
Known drug-gene associations
Key testing
Human leukocyte antigen (HLA) genetic variation is implicated in the development of specific cutaneous adverse reactions to aromatic anticonvulsants. To reduce the incidence of serious, and sometimes fatal, cutaneous adverse reactions to carbamazepine and oxcarbazepine, identifying carbamazepine response and hypersensitivity through HLA-B*15:02 and HLA-A*31:01 genotyping is recommended.5
Known drug-gene associations
Key testing
Tricyclic antidepressants (TCAs)
Select serotonin reuptake inhibitors (SSRIs)
Highlights
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to the most-effective treatment for each patient.
Key testing